Thumbnail Image
Publication

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

Wolleschak, Denise
; 
Mack, Thomas S
; 
Perner, Florian
; 
Frey, Stephanie
; 
Schnöder, Tina M
; 
Wagner, Marie-Christine
; 
Höding, Christine
; 
Pils, Marina C
; 
Parkner, Andreas
; 
Kliche, Stefanie
... show 8 more
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2014-06
Submitted date
Show all metadata
Files
Thumbnail Image
Open Access Publication
Adobe PDF, 2.28 MB
Other Titles
Abstract
Citation
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. 2014, 99 (6):e90-3 Haematologica
Affiliation
Publisher
Journal
Haematologica
URI
http://hdl.handle.net/10033/325037
DOI
10.3324/haematol.2014.104331
PubMed ID
24633870
PubMed Central ID
Additional Links
Embedded video
Type
article
Language
en
Description
Series/Report no.
ISSN
1592-8721
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Archived with thanks to Haematologica
Collections
publications of the research group of immune control (IMMK)